Gene PreDiT Overview

  • Founded
  • 2006
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Gene PreDiT General Information


Developer of a genomic platform intended to identify new genes relevant to certain diseases and identification of compounds with biological activity. The company's platform engages in the discovery of genetic markers and diagnostic tests, as well as in the development of methodologies for the identification of therapeutic targets for diseases especially obesity, enabling physicians to treat the patients in an effective and enhanced manner.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Other Industries
Primary Office
  • Biocant Park - Parque Tecnológico de Cantanhede
  • Núcleo 04, Lote 4-A, Edifício Biocant II
  • Cantanhede, 3060-197
  • Portugal
+351 231 000 000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Gene PreDiT Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 10-Jan-2020 00.000 Completed Generating Revenue
2. Later Stage VC 00.000 Completed Generating Revenue
1. Early Stage VC 23-Jan-2008 $1.25M $1.25M Completed Generating Revenue
To view Gene PreDiT’s complete valuation and funding history, request access »

Gene PreDiT Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Beta, Sociedade de Capital de Risco Venture Capital Minority 000 0000 000000 0
Biocant Ventures Venture Capital Minority 000 0000 000000 0
Inovcapital Venture Capital Minority 000 0000 000000 0
PME Investimentos Investment Bank Minority 000 0000 000000 0
Portugal Ventures Venture Capital Minority 000 0000 000000 0
To view Gene PreDiT’s complete investors history, request access »